Therapeutics

Scientific Library

2013

Therapeutics

PBI-4050 Presentations

European Renal Association, Istanbul Conference Presentations:

Program Number MO012, 50th ERA-EDTA Congress, May 20, 2013:

PBI-4050, a novel first-in-class anti-fibrotic compound, inhibits CTGF, α-SMA and collagen expression in human fibroblasts, and reduces kidney fibrosis in 5/6-nephrectomized and doxorubicin-induced nephrotoxicity models

Program Number TO021, 50th ERA-EDTA Congress, May 21, 2013

PBI-4050, a novel first-in-class anti-fibrotic compound, reduces kidney hyperfiltration, proteinuria, hepatic steatosis, and the expression of inflammatory/fibrotic markers in kidney and liver in diabetic db/db mouse model

PBI-4050, PBI-4419 POSTERS:

European Renal Association, Istanbul Conference Posters:

PBI-4050, a Novel First-In-Class Anti-Fibrotic Compound, Inhibits CTGF and Collagen I Expression in Normal Rat Kidney Fibroblasts and Human Kidney Proximal Tubule Epithelial Cells, and Reduces Kidney Fibrosis in 5/6-nephrectomized Rats

Martin Leduc, Lilianne Geerts, Brigite Grouix, François Sarra-Bournet, Alexandra Felton, Liette Gervais, Shaun Abbott, Jean-Simon Duceppe, Boulos Zacharie, Christopher Penney, Pierre Laurin and Lyne Gagnon

PBI-4419, a Novel First-In-Class Anti-Fibrotic Compound, Inhibits TGF- β-Induced Epithelial-Mesenchymal Transition of Human Renal Tubular HK-2 Cells

Brigite Grouix, Alexandra Felton, François Sarra-Bournet, Martin Leduc, Lilianne Geerts, Liette Gervais, Shaun Abbott, Jean-Simon Duceppe, Boulos Zacharie, Christopher Penney, Pierre Laurin and Lyne Gagnon

World Congress in Nephrology Hong Kong Conference Posters:

Oral Treatment with Novel First-In-Class Anti-Fibrotic Compound PBI-Compound Delays Tubulo-Interstitial Fibrosis in Unilateral Ureteral Obstruction Model

Lyne Gagnon, Lilianne Geerts, André Doucet, François Sarra-Bournet, Martin Leduc, Shaun Abbott, Jean-Simon Duceppe, Boulos Zachary, Christopher Penney, Pierre Laurin and Brigitte Grouix

PBI-Compound, A Novel Orally Active Anti-Inflammatory / Anti-Fibrotic Agent, Reduces Fibrosis in Acute and Chronic Kidney Disease Models

Lyne Gagnon, François Sarra-Bournet, Brigitte Grouix, Kathy Hince, André Doucet, Liette Gervais, Martin Leduc, Alexandra Felton, Jean-Simon Duceppe, Shaun Abbott, Boulos Zachary, Christopher Penney and Pierre Laurin

Intravenous Treatment (Three Times a Week) with PBI-Compound Corrects Anemia, and Reduces Kidney and Heart Fibrosis in 5/6 Nephrectomized (NX) Rats

Lyne Gagnon, André Doucet, Lilianne Geerts, François Sarra-Bournet, Liette Gervais, Pierre Laurin and Brigitte Grouix

Therapeutics

PBI-4419, PBI-4050

PBI-4050, a Novel Orally Active Anti-inflammatory/Anti-fibrotic Agent, Reduces Fibrosis and Sclerosis in 5/6-Nephrectomized Rats
L. Gagnon, F. Sarra-Bournet, B. Grouix, A. Doucet, V. Perron, J.-S. Duceppe, A. Ezzitouni, B. Zacharie, C. Penney and P. Laurin

Nephroprotection: PBI-4419, a Novel Orally Active Antifibrotic Agent, Reduces Doxorubicin-induced Nephrotoxicity in Mice
B. Grouix, K. hince, F. Sarra-Bournet, A. Doucet, S.D. Abbott, J.-F. Bienvenu, J.-S. Duceppe, B. Zacharie, C. Penney, P. Laurin and L. Gagnon

Nephroprotection: PBI-4050, a Novel Orally Active, Anti-inflamatory/Antifibrotic Agent, Reduces Doxorubicin-induced Nephrotoxicity in Mice
B. Grouix, K. hince, A. Doucet, N. Julien, L. Gervais, V. Perron, J.-S. Duceppe, A. Ezzitouni, B. Zacharie, C. Penney, P. Laurin and L. Gagnon

Oral Treatment with a Novel First-in-class Antifibrotic Compound, PBI-4419, Delays tubulointerstitial Fibrosis and Sclerosis in 5/6-Nephrectomized Rats
L. Gagnon, L. Geerts, A. Doucet, F. Sarra-Bournet, S.D. Abbott, J.-F. Bienvenu, J.-S. Duceppe, B. Zacharie, C. Penney, P. Laurin and B. Grouix

PBI-1402

Comparative studies between erythropoietin (EPO) and PBI-1402, a new erythropoiesis-regulating agent (ERA), on murine cancer models (PDF)
Lyne Gagnon, François Sarra‐Bournet, Lilianne Geerts, Kathy Hince, Mouna Lagraoui, Brigitte Grouix, Pierre Laurin and Christopher Penney

Oral treatment of PBI-1402 prevents doxorubicin-induced nephrotoxicity in mice (PDF) Lyne Gagnon, Brigitte Grouix, Nathalie Julien, Mouna Lagraoui, André Doucet, Kathy Hince, François Leblond, Vincent Pichette, Christopher Penney and Pierre Laurin.
American Society of Nephrology 42nd Annual Meeting, San Diego CA, October 2009.

Oral treatment with PBI-1402 increases hemoglobin, hematocrit and red blood cell formation in 5/6 nephrectomized (NX) rats, a model mimicking human end-stage renal disease (ESRD) (PDF)
Lyne Gagnon, François A. Leblond, Brigitte Grouix, Mouna Lagraoui and Vincent Pichette.
American Society of Nephrology 42nd Annual Meeting, San Diego CA, October 2009.

Oral treatment with PBI-1402 improves glomerular filtration rate by reducing tubulo-interstitial fibrosis and sclerosis in 5/6 nephrectomized (NX) rats (PDF)
François A. Lebond, Lyne Gagnon, Brigitte Grouix, Mouna Lagraoui, André Doucet, François Sarra-Bournet, Lilianne Geerts, Christopher Penney, Pierre Laurin and Vincent Pichette.
American Society of Nephrology 42nd Annual Meeting, San Diego CA, October 2009.

A simple and efficient large-scale synthesis of metal salts of medium-chain fatty acids (PDF)
Boulos Zacharie, Abdallah Ezitouni, Jean-Simon Duceppe, Christopher Penney.
Organic Process Research & Development 2009, 13,581-583.

PBI-1402 increases hemoglobin level and red blood cell count in chemotherapy-induced anemia (PDF)
Lyne Gagnon, Jean Barabé, Christopher Penney, Vladimir Kovčin, Snežana Bošnjak and Pierre Laurin.
European Hematology Association 13th Congress, Copenhagen, Danmark, June 12-15, 2008.

Anticancer effect of PBI-0110 in combination with gemcitabine in intradermal and orthotopic pancreatic cancer (PDF)
Lyne Gagnon, Lilianne Geerts, François Sarra-Bournet, Liette Gervais, Brigitte Grouix and Mouna Lagraoui.
American Association of Cancer Research Annual Meeting 2008, San Diego CA, April 12-16, 2008.

Oral treatment with PBI-1402 increases hemoglobin level and red blood cell count: A novel approach to treating chemotherapy-induced anemia (PDF)
Lyne Gagnon, Jean Barabé, Christopher Penney, Denis-Claude Roy, Vladimir Kovčin, Snežana Bošnjak and Pierre Laurin.
American Society of Hematology 49th Annual Meeting, Atlanta GA, December 8-10, 2007.

Autoimmune Diseases

2,4,6-Trisubstituted Triazines as Protein A Mimetics for the Treatment of Autoimmune Diseases (PDF)
Boulos Zacharie, Shaun D. Abbott, Jean-François Bienvenu, Alan D. Cameron, Josée Cloutier, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Karine Houde, Caroline Lauzon, Nancie Moreau, Valérie Perron, Nicole Wilb, Michel Asselin, André Doucet, Marie-Eve Fafard, Dannyck Gaudreau, Brigitte Grouix, François Sarra-Bournet, Natalie St-Amant, Lyne Gagnon, and Christopher L. Penney.
J. Med. Chem. 2010, 53, 1138-1145.

An Efficient Kilogram-Scale Synthesis of N,N-Bis(4,6-disubstituted 1,3,5-triazin-2-yl)-4-aminophenetylamine (PDF)
Jean-Simon Duceppe, Valérie Perron, Josée Cloutier, Christopher Penney, and Boulos Zacharie.
Org. Process Res. Dev. 2009, 13, 1156–116

2,6,9-Trisubstituted purine derivatives as protein A mimetics for the treatment of autoimmune diseases (PDF)
Boulos Zacharie, Daniel Fortin, Nicole Wilb, Jean-François Bienvenu, Michel Asselin, Brigitte Grouix and Christopher Penney. Bioorg. Med. Chem. Lett. 2009, 19, 242-246.

PBI-1308 inhibits inflammation and cancer cell proliferation through inhibition of NF-kB (PDF))
Brigitte Grouix, Marie-Ève Fafard, Dannyck Gaudreau, Yan Vigneault, Lilianne Geerts, Michel Asselin, François Sarra-Bournet, Daniel Fortin, Nicole Wilb, Jean-Simon Duceppe, Valérie Perron, Josée Cloutier, Boulos Zacharie, Christopher Penney and Lyne Gagnon.
American Association of Cancer Research Annual Meeting 2008, San Diego CA, April 12-16, 2008.

Triazine Derivatives as Protein A Mimetcs for the Treatment of Autoimmune Disease (PDF)
1st International Conference on Drug Design & Discovery, Dubai, UAE, February 1-8, 2008.
Presentation by Dr. Boulos Zacharie.

1,3,5-Triazine derivatives with improved solubility for the treatment of inflammatory diseases (PDF)
Boulos Zacharie, Daniel Fortin, Shaun Abbott, Jean-François Bienvenu, Alan Cameron, Josée Cloutier, Jean-Simon Duceppe, Abdallah Ezzitouni, Karine Houde, Caroline Lauzon, Joël Lechasseur, Nancie Moreau, Valérie Perron, Nicole Wilb, Marie-Eve Fafard, Dannyck Gaudreau, Lilianne Geerts, Brigitte Grouix, François Sarra-Bournet, Lyne Gagnon and Christopher Penney.
American Chemical Society 234th National Meeting & Exposition, Boston MA, August 2007.

1,3,5-Triazine Derivatives as Protein A Mimetics for the Treatment of Autoimmune Diseases (PDF)
Boulos Zacharie, Nicole Wilb, Shaun Abbott, Jean-François Bienvenu, Alan Cameron, Josée Cloutier, Jean-Simon Duceppe, Abdallah Ezzitouni, Daniel Fortin, Jean-Hugues Fournier, Karine Houde, Caroline Lauzon, Joël Lechasseur, Nancie Moreau, Valérie Perron, Michel Asselin, Marie-Eve Fafard, Dannyck Gaudreau, Lilianne Geerts, Brigitte Grouix, François Sarra-Bournet, Natalie St-Amant, Lyne Gagnon and Christopher Penney.
American Chemical Society 232nd National Meeting & Exposition, San Francisco CA, September 2006.

Miscellaneous

Synthesis and antimicrobial activity of 2-fluorophenyl-4,6-disubstituted [1,3,5]triazines (PDF)
Mona Saleh, Shaun Abbott, Valérie Perron, Caroline Lauzon, Christopher Penney and Boulos Zacharie.
Bioorg. Med. Chem. Let. 2010, 20, 945-949.

A Method for the Selective Protection of Aromatic Amines in the Presence of Aliphatic Amines (PDF)
Valérie Perron, Shaun Abbott, Nancie Moreau, Devin Lee, Christopher Penney and Boulos Zacharie.
Synthesis 2009, 2, 0283–0289.

Antitumor activity of PBI-1737 in xenograft human prostate (PC-3) cancer by inhibition of cell adhesion and migration (PDF)
Mouna Lagraoui, Brigitte Grouix, Marie-Eve Fafard, Dannyck Gaudreau, Natalie St-Amant, Lilianne Geerts, François Sarra-Bournet, Valérie Perron, Jean-Simon Duceppe, Boulos Zacharie, Christopher Penney and Lyne Gagnon.
American Association of Cancer Research Annual Meeting 2008, San Diego CA, April 12-16, 2008.

Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393 (PDF)
Mustapha Allam, Nathalie Julien, Boulos Zacharie, Christopher Penney and Lyne Gagnon.
Clin. Immunol. 2007, 125(3), 318-327.

In vitro and in vivo modulatory effect of PBI-1393 on LPS-induced neutrophil activation and inflammatory response (PDF)
Mustapha Allam, Nathalie Julien, Michel Asselin, Boulos Zacharie, Christopher Penney and Lyne Gagnon.
The 8th World Congress on Inflammation, Copenhagen Danmark, June 16–20, 2007.

Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cylcophosphamide (PDF)
Salam Kadhim, Christopher Penney, Mouna Lagraoui, Jeffrey Heibein, Giorgio Attardo,  Boulos Zacharie, Timothy Connolly and Lyne Gagnon.
International Journal of Immunopharmacology 2000, 22, , 659-671.

Synthesis and Activity of 6-substituted Purine Linker Amino Acid Immunostimulants (PDF)
Boulos Zacharie, Lyne Gagnon, Giorgio Attardo, Timothy Connolly, Yves St-Denis and Christopher Penney.
J. Med. Chem. 2000, 40, 2883-2894.

 

Protein Technologies

All Clinically Relevant Components, from Prion Infected Blood Donors, can Cause Disease following a Single Transfusion (PDF)
Sandra McCutcheon, Fiona E. Houston, Anthony R. Alejo-Blanco, Christopher de Wolf, Boon Chin Tan,  Anthony Smith, Nora Hunter, Valerie S. Hornsey, Ian R. MacGregor, Christopher V. Prowse, Marc Turner and Jean C. Manson Prion Journal Volume 4 Issue 3

Application of Fabsorbent™ F1P HF, a Synthetic Ligand Adsorbent for Capture and Purification of a Single-Domain Antibody Fragment Expressed in Escherichia coli (PDF)
BioProcess International 7(7) (July - August 2009)

vCJD: An Ongoing Threat to Public Health and its Management (PDF)
Dr. Robert Rohwer, Patient Safety Conference 2010, London, England

An Improved Performance Adsorbent for the Downstream Processing of Serum Albumin and Related Fusion Proteins (PDF)
Bastiaan Lobbezoo, Ben Galarza, Jim Morritt, Chloe Booth, Jennifer Walden and Dev Baines, BioProcess International, Raleigh, NC.

A Synthetic Ligand Affinity Adsorbent for Capture and Purification of Genetically Engineered Antibody Fragment Therapeutics (PDF)
Sharon Williams, Bastiaan Lobbezoo, Michelle Stobbart, Helen Kirkman and Steve Burton, BioProcess International, Raleigh, NC

Characterization of a resin-nonwoven separation medium for removal of prions from complex suspension (PDF)
M.O.Hergistad, P.V.Gurgel, R.G.Carbonell, Prion2009 Conference Chalcidice, Greece

Biochemical quality of the pharmaceutically licensed plasma OctaplasLG(R) after implementation of a novel prion protein (PrPSC) removal technology and reduction of the solvent/detergent (S/D) process time (PDF)
A.Heger, T.-E.Svae, A.Neisser-Svae, S.Jordan, M.Behizad & J.Romisch

Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG(R) (PDF)
A.Neisser-Svae, A.Bailey, L.Gregori, A.Heger, S.Jordan, M.Behizad, H.Reichl, J.Romisch & T.-E.Svae,

In vitro assessment of red-cell concentrates in SAG-M filtered through the MacoPharma™ P-CAPT prion-reduction filter (PDF)
C.V. Murphy, E. Eakins, J. Fagan, H. Croxon & W.G. Murphy, Transfusion Medicine, 2009, 19, 109-116

Prion Infectivity Removal from Human Plasma and Plasma Products Using Affinity Ligands (PDF)
L. Gregori, B. Lambert,P.V. Gurgel, J. Lathrop,M. Behizad, S. Jordan, and R. Rohwer, Plasma Product Biotechnology Meeting 2009Menorca, Spain

The potential for low cost manufacturing of safe plasma products (PDF – Read-only), PPB09 Menorca, Spain - John Curling, Christopher Bryant, Tom Chen, Timothy Hayes, ProMetic BioTherapeutics, Inc., Neil Goss, Further Options Ltd.,Andrew Sinclair, Janice Lim, BioPharm Services Ltd., Mahesh Prashad, Sartorius Stedim Biotech

Alternatives to Protein A capture (PDF) Dev Baines, Sharon Williams, Steve Burton, EuroBiotechNews Nº 3-4, Volume 8, 2009

Determination of Specificity and Capacity for the P-Capt(TM) Prion Removal Filter (PDF) L. Gregori, J.T. Lathrop, P.V. Gurgel, N. Lescoutra, R.G. Rohwer ISBT 2009

Hybrid Particle-Nonwoven Membrane separation Medium for Removal of Pathogenic Contaminants from Red Blood Cell Concentrate (PDF) M.O. Herigstad, P.V. Gurgel, R.G. Carbonnell

Depletion of high abundance proteins from human plasma using a combination of an affinity and pseudo-affinity column (PDF) Urbas L, Brne P, Gabor B, Barut M, Strlic M, Petric TC, Strancar A. J Chromatogr A. 2009; 1216:2689-2694

Development of a Device for Reduction of Prion Infectivity from Red Blood Cell Concentrate (PDF)
P.V. Gurgel, L. Gregori, J. Lathrop, R.G. Carbonell, R. Rohwer, S. Burton
PrPCanada 2009

Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study (PDF)
Simon Mead, Mark Poulter, James Uphill, John Beck, Jerome Whitfield, Thomas EF Webb, Tracy Campbell, Gary Adamson, Pelagia Deriziotis, Sarah J Tabrizi, Holger Hummerich, Claudio Verzilli, Michael P Alpers, John C Whittaker, John Collinge
Lancet Neural 2009;8:57-66

Specificity and capacity of the P-Capt(R) filter for prion protein and prion infectivity (PDF)
Prion 2008

Reduction of prion from red cells, plasma and plasma products using specific affinity ligands (PDF)
Prion 2008

Removal of prion infectivity from plasma-derived products (PDF)
Recovery of Biological Products 13 Conference

Prion Safety and Transfusion Plasma Abstract Book (PDF)
30th International Congress of the International Society of Blood Transfusion, June 7-12, 2008, Presentation by Octapharma

The introduction of a novel prion protein (PrPSc) removal technology for the pharmaceutically licensed plasma Octaplas® (PDF)
30th International Congress of the International Society of Blood Transfusion, June 7-12, 2008, Presentation by Octapharma

Biochemical quality of the pharmaceutically licensed plasma Octaplas® after implementation of a novel prion protein (PrPSc) removal technology (PDF)
30th International Congress of the International Society of Blood Transfusion, June 7-12, 2008, Presentation by Octapharma

Development of a device for prion reduction based on affinity ligand (PDF)
235th Annual Chemical Society Meeting, April 6-10, 2008. Presentation by Dr. Patrick Gurgel

Managing the risks from blood associated TSE infectivity with prion affinity ligands (PDF)
235th Annual Chemical Society Meeting, April 6-10, 2008. Presentation by Dr. R. Rohwer

Process Chromatography – Five Decades of Innovation (PDF)
Curling J.M.
Biopharm International, February 2007

Reduction of transmissible spongiform encephalopathy infectivity from human red blood cells with prion protein affinity ligands (PDF)
Luisa Gregori, Brian C. Lambert, Patrick V. Gurgel, Liliana Gheorghiu, Peter Edwardson, Julia T. Lathrop, Claudia MacAuley, Ruben G. Carbonell, Steven J. Burton, David Hammond, and Robert G. Rohwer
Transfusion, Volume 46, pp. 1152-1161, July 2006

Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins (PDF)
Luisa Gregori, Patrick V Gurgel, Julia T Lathrop, Peter Edwardson, Brian C Lambert, Ruben G Carbonell, Steven J Burton, David J Hammond, Robert
G Rohwer
Lancet 2006; 368: 2232–36

Prion reduction filters (PDF)
Marc L Turner, Edinburgh Blood Transfusion Centre, Royal Infi rmary of Edinburgh
Lancet 2006; Vol 368 December 23/30

The Plasma Fractionation Industry. New Opportunities To Move Forward? (PDF)
Curling, J.M. and Bryant, C.
BioProcess International, March 2005

New Challenges for Biopharmaceutical Process Development (PDF)
Curling, J.M.
Biotechnology Focus, February 2005

Affinity chromatography – from textile dyes to synthetic ligands by design. Part 2
Curling, J. M.
BioPharm Intl. 17, No. 8, 60-66, August 2004.

Affinity chromatography – from textile dyes to synthetic ligands by design. Part 1
Curling, J. M.
BioPharm Intl. 17, No. 7, 34-42, July 2004.

Integrating new technology into blood plasma fractionation
Curling, J. M.
BioPharm 15, No. 9, 16-25, September 2002.

Affinity Chromatography
Smiley, L., and Curling, J.M.
Genetic Engineering News, November 15, 2001.

Comparing the Safety of Synthetic and Biological Ligands Used for Purification of Therapeutic Proteins
Behizad, B., Curling, J.M.
Biopharm, Vol 13 No 7 pp. 42–46., September 2000.

Development and Commercialization of Biomimetics
Burton, J.
Link, Collaborative Research, 2000.

Regulatory Aspects of Column chromatography in Biopharmaceutical Manufacturing
Behizad, M., Baines, D.
Biopharm Vol 11 No 5, May 1998.

Design, Synthesis, and Application of a Protein A Mimetic
Li, Rongxiu., Dowd, V., Stewart, D.J., Burton, S.J., Lowe, C.R.
Nature Biotechnology, Vol 16, pp. 190–195, February 1998.